FDA expands approval of Adcetris for first-line treatment of Stage III or IV cHL
The FDA approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. The FDA granted the approval of Adcetris to Seattle Genetics. March 20, 2018